EpiAxis Board

Charles Lindop – Director

Charles is an experienced technology industry corporate advisor, working as a principal of KTM Capital, on M&A, equity finance and IPOs. Recent work includes BGH Capital cyber/cloud investee CyberCX, where Charles led all the M&A and Investment deals. Other engagements led by Charles include the acquisition of HiVint by Singtel Optus, Bearing Point Australia by Pactera, Business Aspect by Data#3, and Markinson by Constellation Software.

Jeremy Chrisp – Director

Jeremy is a biotechnology entrepreneur with extensive experience in the commercialisation of Australian technology, with a focus on business development and the management of early stage opportunities. Jeremy holds a PhD in physiology from the University of Canterbury (NZ) and is a Fellow of the Australian Institute of Company Directors (AICD). He has more than 30 years experience in the Australian healthcare market, initially by working with leading global multinational companies, including Merck & Co, Stryker, Becton Dickinson & Medtronic.

Rob McInnes – Director

Rob is one of Australia’s leading biotech IP specialists having initially trained as a protein chemist before turning to commercial law, specialising in intellectual property transactions. He is currently the principal of Rob McInnes IP Advisory, which he founded after practising for 30 years in large law and patent attorney firms.  McInnes advises clients on the management and commercialisation of IP rights, with a focus on planning, negotiating and structuring licence agreements and R&D contracts.

For the past decade Rob has been ranked as Australia’s most highly recommended patent and technology licensing lawyer and is one of the few Australian lawyers to have met the requirements for the US-based Certified Licensing Professional qualification. He is an active Sydney Angels investor and a mentor or expert-in-residence at a number of start-up incubators.